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See related research by Launey et al. http://ccforum.com/content/18/6/689We read with interest the paper by Launey and col-
leagues [1] regarding the effect of fever control on the
incidence of ventilator-associated pneumonia (VAP) in
brain-injured patients. We commend the authors for ad-
dressing this relationship, given that fever and nosoco-
mial infections are frequent in these patients. However,
we have concerns regarding the interpretation of data.
Firstly, independent risk factors for VAP, namely dis-
ease severity and lung contusion [2,3], are unevenly dis-
tributed between groups. In addition, other risk factors,
such as chronic obstructive pulmonary disease (COPD)
and ICU readmission [2,4], were not taken into account,
suggesting any effect of fever control is likely subject to
confounding.
Secondly, mortality in the control group was higher
(34% versus 23%), lowering the observation period if
death occurred within 28 days. Thus, patients in the* Correspondence: m.harmon@amc.uva.nl
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unless otherwise stated.fever-control group were observed for a longer period of
time, increasing their time at risk for VAP.
Thirdly, VAP incidence was higher in patients who
were subject to fever control for longer than 3 days.
However, duration of fever control was likely determined
by factors also affecting the patients’ risk of acquiring
VAP; that is, death. Not surprisingly, those who died
within 3 or fewer days of initiating fever control did not
develop VAP as frequently as those who did not.
In summary, the intervention group and historical
control group in this study do not seem to be optimally
matched on crucial parameters. Additionally, decreased
mortality and longer follow-up in the intervention group
likely resulted in uncontrolled lead time bias/attrition
bias. Decreased mortality also seems contradictory to
the claim that VAP, a deadly condition for ICU patients,
is more frequent among fever-control patients.t and Philippe SeguinWe thanks Dr Harmon and colleagues for their com-
ments, which we would like to nuance.
Indeed, COPD was not reported at admission; how-
ever, such disease is clearly unusual in the studied popu-
lation. In a recent multicentre study performed in the
same population, a history of respiratory disease (includ-
ing COPD) was observed in only 3.6% [5]. Secondly,
none of the included patients were readmitted in our
ICU during the first 28 days of ICU stay, which was the
endpoint period to assess VAP occurrence.
As reported in the statistical section, we used a com-
peting risk multivariate model [6] which considers deathwithin 28 days as a competing event. Consequently, this
model takes into account only the periods of time during
which the patients were exposed to the risk of VAP.
Moreover, the benefit of this model is that the death
event is not a confounding factor in the determination
of VAP incidence between the patients receiving fever
control for longer than 3 days and those who did not.
The size of the study was not large enough to reach stat-
istical significance.
Finally, we acknowledge that the matching of the two
groups was not optimal in our observational study and
obviously a prospective randomized study is required.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Harmon et al. Critical Care  (2015) 19:208 Page 2 of 2Nevertheless, we would like to emphasize our study
was not designed to assess the impact of fever-control
strategy on mortality and, despite the apparent results,
no conclusion can be drawn on mortality. Moreover, a
recent meta-analysis showed VAP was not associated with
over-mortality in medical and trauma patients [7].
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